Compare TG Therapeutics Inc (TGTX) vs State Street PDR S&P Retail ETF (XRT) Price & Performance

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.

XRT (SPDR S&P Retail ETF) trades at $88.83, down 1.94% on the day, with technical indicators showing a bullish overall signal despite recent weakness. The ETF maintains neutral oscillators but strong directional movement indicators. Recent retail sales data shows five consecutive months of consumer spending growth, though sentiment remains challenged by inflation pressures and energy costs. The ETF provides diversified exposure to the retail sector with upcoming dividend distribution scheduled for June 2026.

The retail sector faces mixed signals with sustained consumer spending but macroeconomic headwinds. XRT's technical setup suggests potential near-term support around $88-89 levels, while fundamental exposure to discretionary retail remains sensitive to consumer confidence and inflation trends. Key risks include deteriorating consumer sentiment and competitive pressures within the retail landscape.